FDA Announces Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection Vials Due to Glass Particles

Fresenius Kabi has issued a nationwide recall for one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL vials after an internal investigation revealed the presence of glass particles. The administration of injectable products containing glass particulates can lead to local irritation, pain, swelling, or inflammation of the veins. Tyenne is used to treat various conditions, including rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis, CAR T cell-induced cytokine release syndrome, and certain hospitalized COVID-19 patients.